{
    "organizations": [],
    "uuid": "9f13448ec482136493229e196f01d31842fe4e99",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-announces-new-phase-2-data/brief-abbvie-announces-new-phase-2-data-for-upadacitinib-showing-clinical-and-endoscopic-outcomes-in-crohns-disease-at-52-weeks-idUSFWN1Q61BU",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News February 16, 2018 / 4:56 PM / in 8 minutes BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks Reuters Staff 1 Min Read Feb 16 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN‘S DISEASE AT 52 WEEKS * ABBVIE INC - ‍PHASE 3 TRIALS FOR UPADACITINIB IN CROHN‘S DISEASE ARE ONGOING​ * ABBVIE - ‍OVERALL SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH THAT OBSERVED IN OTHER UPADACITINIB STUDIES, WITH NO NEW SAFETY SIGNALS DETECTED​ * ABBVIE - ‍MANY UPADACITINIB-TREATED PATIENTS WHO ACHIEVED CLINICAL RESPONSE§ AFTER 16-WEEK INDUCTION PHASE MAINTAINED RESPONSE AFTER 36-WEEK EXTENSION ​ * ABBVIE INC - ‍ 2 MALIGNANCIES OCCURRED IN 12 MG TWICE-DAILY ARM AND NO DEATHS OCCURRED IN CELEST STUDY​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-16T18:54:00.000+02:00",
    "crawled": "2018-02-16T19:15:07.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "february",
        "pm",
        "minute",
        "announces",
        "new",
        "phase",
        "data",
        "upadacitinib",
        "showing",
        "clinical",
        "endoscopic",
        "outcome",
        "crohn",
        "disease",
        "week",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "announces",
        "new",
        "phase",
        "data",
        "upadacitinib",
        "showing",
        "clinical",
        "endoscopic",
        "outcome",
        "crohn",
        "disease",
        "week",
        "abbvie",
        "inc",
        "trial",
        "upadacitinib",
        "crohn",
        "disease",
        "abbvie",
        "safety",
        "profile",
        "upadacitinib",
        "consistent",
        "observed",
        "upadacitinib",
        "study",
        "new",
        "safety",
        "signal",
        "abbvie",
        "patient",
        "achieved",
        "clinical",
        "induction",
        "phase",
        "maintained",
        "response",
        "extension",
        "abbvie",
        "inc",
        "malignancy",
        "occurred",
        "mg",
        "arm",
        "death",
        "occurred",
        "celest",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}